Dr. Aaron Paul Rapoport, MD

Dr. Rapoport practices at University of Maryland Medical Center in Baltimore, Maryland, part of University of Maryland Medical System.

Dr. Rapoport's NPI, 1356309280, was assigned on May 2, 2006. Dr. Rapoport graduated from Harvard Medical School in 1986. Dr. Rapoport's Maryland license number on file is D52477.

Dr. Rapoport's primary practice is University of Maryland Medical Center, at 22 South Greene Street, Baltimore, MD 21201 in Baltimore City. The practice phone is (410) 328-8667.

Dr. Rapoport's primary practice is University of Maryland Medical Center in Baltimore, Maryland, part of University of Maryland Medical System. The medical group on file is University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center (UMGCCC).

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Rapoport practices. Vendor and product names are available with a free account.

Internal medicine is Dr. Rapoport's primary specialty in the NPI Registry, under taxonomy code 207RH0000X. The record also lists hematology. Dr. Rapoport is board certified in hematology by the American Board of Internal Medicine. Dmand AI has Dr. Rapoport's licenses on file in 3 states: Maryland, Pennsylvania and New York.

Dmand AI lists chronic anemia, chronic leukemia, lymphoma and multiple myeloma among the conditions Dr. Rapoport treats.

CMS data shows 548 Medicare services from Dr. Rapoport across 6 procedure codes in 2024, for 168 Medicare patients. Medicare paid $50,405 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 168 Medicare patients who saw Dr. Rapoport in 2024. The largest group is 65 to 74, with 90 patients. 75% of them have high cholesterol, and 71% have high blood pressure. 9% are also on Medicaid. Their average risk score is 2.64, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Rapoport's median patient age at 70, with 38% women.

In 2024, Dr. Rapoport wrote 565 Medicare Part D claims for 76 patients. 83% of them were for generic drugs. CMS names the drug for 385 of them, across 13 drugs with 11 or more claims each, at $721,179 in total drug cost. In 2023, CMS named 415 claims across 15 drugs.

Dr. Rapoport accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 157 papers to Dr. Rapoport, published from 2005 to 2025. 2024 was the busiest year, with 9. The most frequent topics are Immunotherapy, Adoptive, Multiple Myeloma and Hematopoietic Stem Cell Transplantation. Dr. Rapoport has published most often in Bone Marrow Transplant. Dr. Rapoport's most frequent co-authors are Saurabh Dahiya, MD, Ashraf Zarif Badros, MD and Jean A. Yared, MD.

Dmand AI links Dr. Rapoport to 12 clinical trials, 5 of them phase 2 studies. 1 is still active or recruiting. Conditions studied include Multiple Myeloma, Blood Protein Disorders and Anemia, Aplastic. University of Maryland, Baltimore sponsors the most, 4.

CMS Open Payments shows 8 general payments to Dr. Rapoport from 6 drug and device companies from 2017 to 2025. Food and beverage make up the largest share, 100% of the total. Kite Pharma, Inc. paid the most, $165.

Dmand AI lists 6 awards for Dr. Rapoport, most recently America's Top Doctors in 2014.

Dr. Rapoport graduated from Harvard Medical School in 1986. Dr. Rapoport is a member of ACP.

Dr. Rapoport is in network with 15 carriers, including Aetna, Excellus BlueCross BlueShield and Blue Cross Blue Shield of Michigan. Medicare plans come from the most carriers, 12. Check the plan with the practice before a visit.